Large pharma companies are posting 530% more tweets a week than in 2013, a study by Ogilvy Healthworld found. The healthcare communications group tracked the social media activity of 14 large pharma companies for one week per month over three months.
DNAnexus has snagged $15 million from WuXi PharmaTech in a Series D round. The deal will see DNAnexus bring its cloud-based genomics platform to China and pair it with WuXi NextCODE's offering.
Eli Lilly, Novartis and Pfizer have found a new home for the tech they created to improve ClinicalTrials.gov. The group is giving what it has achieved to date to TrialReach, a tech company developing a patient-focused clinical trial discovery platform.
Edico Genome has hooked up with Intel in an attempt to shave more minutes off the time it takes to analyze a whole genome. The partnership brings together Edico's NGS analysis hardware and the Intel Xeon microprocessors that reside in many servers used in genomics.
Quest Diagnostics has teamed up with French human health research institute Inserm to pool and share BRCA1 and BRCA2 genetic data. LabCorp has signed up as the first participant in the program, giving it a sizable reach from day one.
Bina Technologies has unveiled its first publicly known deal with a Big Pharma since it was bought by Roche. The agreement sees AstraZeneca tighten its ties to the genomic data analysis platform provider by becoming the first member of the Bina Alliance Program.
The World Health Organization has updated its position on the disclosure of clinical trial data. Having advocated greater use of registries back in 2005, WHO now wants to see the establishment of a more integrated IT system that includes data from new and old clinical trials.
Sanofi is suing startup Diagnosia over the publication of information about side effects and drug interactions in its physician decision support software.
California has become the latest government to set up a precision medicine initiative. And like President Barack Obama's nationwide plan, the success of the state initiative will rest in part on whether it can combine and make sense of different sources of data.
Apple just gained a powerful ally in its push to make ResearchKit a core component of the health research toolkit. The Silicon Valley tech giant has tapped IBM for access to Watson, the data-mining and predictive analytics capabilities of which will be applied to health research.
A survey by analysts at William Blair has found that biopharma R&D staffers think making better use of existing data is their best hope of improving productivity. Almost half of the 133 respondents said the topic was the biggest remaining opportunity to improve R&D.
PatientsLikeMe has struck a 5-year deal to support R&D at AstraZeneca. The agreement tops off a busy and important 12 months for the patient network, in which it has also expanded relationships with Biogen, Roche's Genentech and Swiss biopharma Actelion.
Peking University Clinical Research Institute is trying to drag China into the eClinical era by expanding its alliance with Medidata. Under the terms of the revised relationship, the partners will help local drug developers access electronic data capture tools and other eClinical technologies.
BioXcel has added another big name to its list of clients. Takeda is the latest company to sign up to work with BioXcel, a database-driven drug discovery shop that already boasts relationships with Alexion, Sanofi, Teva and Vertex.
TrialScope has created a free online tool that converts XML files formatted for uploading to ClinicalTrials.gov to the template used by its European equivalent, EudraCT.
Feedback from an early-access program for Synthetic Genomics' personal DNA workstation has started to emerge. And the initial news is positive, with a researcher at the University of California, San Francisco, reporting that the device is cutting the time and money it takes to synthesize DNA.
Nature Biotechnology is encouraging authors of computational biology papers to publish their source code on GitHub as part of a company-wide drive to ensure research is reproducible. The policy is designed to counter long-standing concerns about the peer review of computation-heavy research.
Eisai has added to its genomics capabilities. The latest move sees the Japanese drugmaker's nascent Integrated Human Genomics (IHGx) Research Unit team up with Genomics plc, an Oxford University spinout founded in response to the United Kingdom's 100,000 Genomes Project.
Schrödinger has racked up another tech-validating deal. Having seen the biotech it helped to found rake in $43 million from Pfizer and others last month, the computational drug design veteran has now struck a $120 million discovery deal with Sanofi.
The fight for top bioinformatics talent is heating up. With 23andMe poaching Robert Gentleman from Genentech, the Roche-owned Big Biotech now finds itself competing with the likes of Google's Calico in its hunt for a replacement.